Non-Myeloablative Chemotherapy Followed by Unrelated Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies: A Pilot Study
OBJECTIVES: I. Determine the feasibility of allogeneic engraftment after unrelated matched
allogeneic peripheral blood stem cell transplantation preceded by a nonmyeloablative,
fludarabine based conditioning regimen in patients with advanced hematologic malignancies.
II. Determine the toxicities of this regimen, especially graft versus host disease, in these
OUTLINE: Patients receive fludarabine IV over 30-60 minutes on days -7 to -4,
cyclophosphamide IV over 30 minutes on days -7 to -5, and cytarabine IV over 2 hours on days
-4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Filgrastim (G-CSF)
is administered IV over 1 hour or subcutaneously beginning on day 1 and continuing until
blood counts recover. Patients are followed weekly until day 60 and then monthly for 10
PROJECTED ACCRUAL: A total of 6 patients will be accrued for this study.
Primary Purpose: Treatment
Christos E. Emmanouilides, MD
Jonsson Comprehensive Cancer Center
United States: Federal Government